Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Disease 1

Interventions

Blood Specimen Collection 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3Surveys and Questionnaires 2Prednisone 2Positron-Emission Tomography 2Magnetic Resonance Imaging 2Injections 2vistusertib 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1pembrolizumab 1lortalamine 1ioflupane 1gossypol acetic acid 1carbon-11 acetate 1abiraterone 1Waiting Lists 1Urine Specimen Collection 1Urination 1Transcutaneous Electric Nerve Stimulation 1Therapeutics 1Specimen Handling 1Referral and Consultation 1Prostatectomy 1Preoperative Exercise 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Observation 1Music Therapy 1Multiparametric Magnetic Resonance Imaging 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Food × Genitourinary × Clear all
NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

SMED Clinical Research

Phase 2 Recruiting
60 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡